View Clinical Trial (Medical Research Study)
Dynamic Contrast Enhanced MRI (DCE-MRI) Diffusion Weighted MRI (DW-MRI) and Magnetic Resonance Spectroscopy (MRS) of Head and Neck Tumors
| City: |
|
New York |
| State: |
|
New York |
| Zip Code: |
|
10065 |
| Conditions: |
|
Head and Neck Cancer |
| Purpose: |
|
Magnetic resonance imaging (MRI) is a diagnostic study that makes pictures of organs of the
body using magnetic field and radio frequency pulses that can not be felt. Dynamic contrast
enhanced-magnetic resonance imaging (DCE-MRI) uses faster imaging and contrast material (a
substance used to make specific organs, blood vessels, or tumors easier to see) that is
given by vein. Diffusion weighted magnetic resonance imaging (DW-MRI) allows to measure the
motion of water around the cells in the tumor. Proton magnetic resonance spectroscopy (MRS)
obtains chemical information from the tumor. During MRS, signals are detected from the
chemicals (spectroscopy) naturally present in your tumor using radio waves. DCE-MRI, DW-MRI
and MRS give extra information which is not available with the regular MRI. The regular MRI
only shows pictures of the tumor while the DCE-MRI also gives information about the blood
vessels of the tumor. DW-MRI provides information related to the state of the tumor tissue
with regards to the quality or condition of cells present in it and MRS gives information
about the chemical makeup of the tumor.
The purpose of this study is to see whether DCE-MRI, DW-MRI and MRS done before treatment
can predict which patients will do well with either surgery or chemo-radiation therapy. This
study will also see if DCE-MRI, DW-MRI and MRS done early in treatment can tell if the
therapy is working.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Patients with histologically proven diagnosis of head and neck cancer or patients
with tumors strongly suspicious for head and neck cancer due to clinical features or
FNA (fine needle aspiration) cytology assessment.
- Will undergo surgery or chemo-radiation treatment
- Presence of evaluable primary tumor
- Patients must be 18 years or older and have the ability to give informed consent
Exclusion Criteria:
- Claustrophobia
- Absence of evaluable primary tumor
- Known reaction to Gd-DTPA
- Pre-operative radiation to primary tumor site
- Contraindication to MRI
1. Pacemaker
2. Aneurysmal clips
3. Metal implants in field of view
4. Pregnant or nursing women
5. Age and mental status wherein he/she is unable to cooperate for MRI study
|
| NCT ID: |
|
NCT00581906 |
| Primary Contact: |
|
Principal Investigator
Amita Dave, PhD
Memorial Sloan-Kettering Cancer Center
Amita Dave, PhD
Phone: 212-639-3184
|
| Backup Contact: |
|
Hilda Stambuk,, MD
Phone: 212-639-2728
|
| Location Contact: |
|
New York, New York 10065
United States
Amita Dave, PhD
Phone: 212-639-3184
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 23, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|